4-甲酰基苯磺酸 | 5363-54-2

• 物质功能分类: 化学试剂 - 有机试剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲酰基苯磺酸
• 英文名称: benzaldehyde-4-sulfonic acid
• 英文别名: 4-(sulfoxonium) benzaldehyde；p-formylbenzenesulfonic acid；4-formylbenzenesulfonic acid；4-sulphobenzaldehyde；4-formyl-benzenesulfonic acid；4-Formyl-benzolsulfonsaeure
• CAS: 5363-54-2
• 化学式: C₇H₆O₄S
• 分子量: 186.188
• InChiKey: XSAOGXMGZVFIIE-UHFFFAOYSA-N

物化性质

• 熔点：
  121.5-123.0 °C
• 密度：
  1.503±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2913000090

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  对甲苯磺酸	toluene-4-sulfonic acid	104-15-4	C7H8O3S	172.205
  4-磺基苯甲酸酯	4-sulphobenzoic acid	636-78-2	C7H6O5S	202.188

反应信息

• 作为反应物：
  描述：

  1,10-邻二氮杂菲-5,6-二酮 、 4-甲酰基苯磺酸 在 ammonium acetate 、 溶剂黄146 作用下， 反应 0.33h， 以51.4%的产率得到4-(1H-imidazo[4,5-f][1,10]phenanthrolin-2-yl)benzenesulfonic acid
  参考文献：
  名称：

  Microwave-assisted synthesis of phenanthroimidazole derivatives as stabilizer of c-myc G-quadruplex DNA

  摘要：

  c-myc G-quadruplex DNA, which plays a central role in tumor progression and resistance, has been extensively investigated as potential target of antitumor drugs. In this paper, a series of phenanthroimidazole derives have been synthesized under irradiation of microwave in yields of 51-80%. The antitumor activity of these compounds against various tumor cells has been evaluated, and the results show that these compounds exhibit great inhibition to MDA-MB-231, MCF-7 and Hela cells, especially 5 inhibit the growth of MDA-MB-231 cells with IC50 about 3.6 mu M. The further studies show that 5 can bind and stabilize c-myc G4 DNA in pi-pi stacking mode, which confirmed by the hypochromise in the electronic spectra of 5 with the increasing of c-myc G4 DNA. When dealt with 5, the strength of CD signal attributed to c-myc G4 DNA is decreased and the FRET melting point of c-myc G4 DNA is increased. Moreover, the molecule docking calculation was conducted to show that 5 suitably stack onto the 50 G-quartet surface, and parallels to the surfaces of the G5 and G-quartet consisting of G7, G11, G16, and G20. As a result, the replication of c-myc oligomers is blocked by 5. In a word, this type of phenanthroimidazole derives can act as potential inhibitor against breast cancer cells by binding and stabilizing c-myc G4 DNA through p-p stacking. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.09.003
• 作为产物：
  描述：

  乙酰氧基-(4-氯磺酰基苯基)乙酸甲酯 在 盐酸 作用下， 生成 4-甲酰基苯磺酸
  参考文献：
  名称：

  Stuenzi, Hans, Australian Journal of Chemistry, 1981, vol. 34, # 12, p. 2549 - 2561

  摘要：

  DOI：

文献信息

• Method for Producing Compound Containing BIS (Perfluoroalkylsulfonyl) Methyl Group and Salt Thereof, and Solid Electrolyte Membrane Produced Using Same
  申请人：CENTRAL GLASS COMPANY, LIMITED

  公开号：US20150266816A1

  公开（公告）日：2015-09-24

  [Problem] To provide a method for producing a compound having a bis(trifluoroalkanesulfonyl)methyl group, which is a compound having a high acidity degree and hydrophobicity and useful as a raw material compound for a resin, and a salt thereof in a simple manner. [Solution] A method for producing a compound containing a bis(perfluoroalkylsulfonyl)methyl group and represented by the following formula and a salt of the compound. (Rf represents a perfluoroalkyl group having 1 to 12 carbon atoms. A represents a monovalent organic group. Y represents a single bond or a C 1 -C 4 linear, C 3 -C 4 branched or C 3 -C 4 cyclic alkylene group wherein each of some or all of hydrogen atoms may be substituted with a fluorine atom, a chlorine atom, a bromine atom or an iodine atom and an ether bond or an ester bond may be contained.)

  提供一种简单的方法，用于生产具有高酸度和疏水性的双(三氟烷磺酰基)甲基基团的化合物，该化合物可作为树脂的原料化合物，并提供该化合物的盐。生产含有双(全氟烷基磺酰基)甲基基团的化合物及其盐的方法如下所示： （Rf代表具有1至12个碳原子的全氟烷基基团。A代表一价有机基团。Y代表单键或C1-C4线性、C3-C4支链或C3-C4环烷基基团，其中部分或全部氢原子可被氟原子、氯原子、溴原子或碘原子取代，并且可能包含醚键或酯键。）
• 1,4-dihydropyridines
  申请人：Bayer Aktiengesellschaft

  公开号：US04686229A1

  公开（公告）日：1987-08-11

  1,4-Dihydropyridines of the formula ##STR1## in which R.sup.1 is hydrogen, or alkyl optionally substituted by halogen, nitro, cyano, alkoxy, carboxyl, alkoxycarbonyl or carboxamide, R.sup.2 is hydrogen or alkyl, R.sup.3 is hydrogen, alkyl, carboxyl, alkoxycarbonyl or aryl optionally substituted by hydroxyalkyl, carboxyl, sulphoxy, acloxyalkyl, or ##STR2## R.sup.4 is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, ##STR3## X is oxygen, sulphur or NH, and n is 1 to 6, or physiologically acceptable salts thereof, which are active in combating thromboembolic and ischaemic disorders.

  公式为##STR1##的1,4-二氢吡啶，其中R.sup.1是氢，或者由卤素，硝基，氰基，烷氧基，羧基，烷氧羰基或羧酰胺取代的烷基，R.sup.2是氢或烷基，R.sup.3是氢，烷基，羧基，烷氧羰基或芳基，可以由羟基烷基，羧基，磺氧基，乙氧基烷基或##STR2##取代，R.sup.4是烷基，芳基，杂芳基，芳基烷基，杂芳基烷基，##STR3## X是氧，硫或NH，n为1至6，或其生理上可接受的盐，对抗血栓栓塞和缺血性疾病具有活性。
• MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS
  申请人：Genomatica, Inc.

  公开号：US20150148513A1

  公开（公告）日：2015-05-28

  The invention provides non-naturally occurring microbial organisms having a 4-hydroxybutyrate, 1,4-butanediol, or other product pathway and being capable of producing 4-hydroxybutyrate, 1,4-butanediol, or other product, wherein the microbial organism comprises one or more genetic modifications. The invention additionally provides methods of producing 4-hydroxybutyrate, 1,4-butanediol, or other product or related products using the microbial organisms.

  该发明提供了具有4-羟基丁酸、1,4-丁二醇或其他产物途径并能够产生4-羟基丁酸、1,4-丁二醇或其他产物的非自然微生物生物体，其中该微生物生物体包括一个或多个基因修饰。该发明还提供了利用这些微生物生物体生产4-羟基丁酸、1,4-丁二醇或其他产物或相关产品的方法。
• DIHYDROOXAZOL-2-AMINE DERIVATIVES
  申请人：Nettekoven Matthias

  公开号：US20120108609A1

  公开（公告）日：2012-05-03

  The invention relates to compounds of formula wherein R 1 , R 2 , R 3 , R 4 , X, Ar, and are defined herein or to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm and cardiovascular disorders.

  本发明涉及以下结构的化合物，其中R1、R2、R3、R4、X、Ar和在此处定义，或其药用合适的酸盐。公式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对于TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、双相情感障碍、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用以及代谢性障碍如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。
• [EN] DIHYDROOXAZOL-2-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE DIHYDROOXAZOL-2-AMINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012059371A1

  公开（公告）日：2012-05-10

  The invention relates to compounds of formula (I) wherein R1 is hydrogen or lower alkyl; R2 is hydrogen or is heteroaryl, optionally substituted by one or more halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, S-lower alkyl, S(O)-lower alkyl, S(O)2-lower alkyl, C(O)-lower alkyl or C3-6-cycloalkyl; R3 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, S-lower alkyl, S(O)-lower alkyl, S(O)2-lower alkyl, C(O)-lower alkyl or C3-6-cycloalkyl; R4 is hydrogen or lower alkyl; (A) is phenyl or pyridinyl, wherein the N-atom may be in different positions; X is a bond or CH(CF3)-; Ar is aryl or heteroaryl, optionally substituted by one or more R3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm and cardiovascular disorders.

  该发明涉及公式(I)的化合物，其中R1是氢或较低的烷基；R2是氢或是杂环芳基，可选择地被一个或多个卤素、较低的烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基、氰基、S-较低烷基、S(O)-较低烷基、S(O)2-较低烷基、C(O)-较低烷基或C3-6-环烷基取代；R3是氢、卤素、较低烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基、氰基、S-较低烷基、S(O)-较低烷基、S(O)2-较低烷基、C(O)-较低烷基或C3-6-环烷基；R4是氢或较低烷基；(A)是苯基或吡啶基，其中N原子可能在不同位置；X是键或CH(CF3)-；Ar是芳基或杂环芳基，可选择地被一个或多个R3取代；或其药学上适宜的酸盐。现在发现公式I的化合物对痕量胺相关受体（TAARs）有很好的亲和性，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑症、躁郁症、注意力缺陷多动障碍（ADHD）、与压力有关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。